Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total
Stockholders' Equity, Beginning Balance at Dec. 31, 2020	$ 37	$ 430,324	$ (134)	$ (275,907)	$ 154,320
Shares, Outstanding, Beginning Balance at Dec. 31, 2020	37,368,027
Exercises of vested stock options	$ 1	27			28
Exercises of vested stock options (in shares)	3,811
Vesting of restricted stock units (in shares)	346,551
Issuance of common stock under ESPP		918			918
Issuance of common stock under ESPP (in shares)	200,006
Stock based compensation expense		10,990			10,990
Unrealized gain (loss) on available-for-sale securities, net of tax			(4)		(4)
Net income (loss)				(71,197)	(71,197)
Stockholders' Equity, Ending Balance at Dec. 31, 2021	$ 38	442,259	(138)	(347,104)	95,055
Shares, Outstanding, Ending Balance at Dec. 31, 2021	37,918,395
Exercises of vested stock options		629			629
Exercises of vested stock options (in shares)	89,012
Vesting of restricted stock units (in shares)	456,219
Issuance of common stock under ESPP		672			672
Issuance of common stock under ESPP (in shares)	150,265
Stock based compensation expense		9,153			9,153
Unrealized gain (loss) on available-for-sale securities, net of tax			(81)		(81)
Net income (loss)				(46,408)	(46,408)
Stockholders' Equity, Ending Balance at Dec. 31, 2022	$ 38	452,713	(219)	(393,512)	59,020
Shares, Outstanding, Ending Balance at Dec. 31, 2022	38,613,891
Exercises of vested stock options	$ 1	1,851			$ 1,852
Exercises of vested stock options (in shares)	385,655				385,655
Vesting of restricted stock units (in shares)	531,560
Issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement	$ 5	31,116			$ 31,121
Issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement (in shares)	4,395,588
Issuance of common stock under ESPP		959			959
Issuance of common stock under ESPP (in shares)	111,639
Stock based compensation expense		10,867			10,867
Unrealized gain (loss) on available-for-sale securities, net of tax			171		171
Net income (loss)				132,330	132,330
Stockholders' Equity, Ending Balance at Dec. 31, 2023	$ 44	$ 497,506	$ (48)	$ (261,182)	$ 236,320
Shares, Outstanding, Ending Balance at Dec. 31, 2023	44,038,333